<?xml version='1.0' encoding='utf-8'?>
<document id="27504556"><sentence text="AParadigm Shift: The New Novel Oral Anticoagulation Agents." /><sentence text="Atrial fibrillation (AF) is the most common arrhythmia and represents one-third of the arrhythmia-related hospital admissions in the developed countries" /><sentence text=" Embolic strokes associated with AF are more severe and disabling" /><sentence text=" Thromboembolic stroke prevention is a major goal in treatment of AF and Warfarin has successfully served this purpose for many years"><entity charOffset="73-81" id="DDI-PubMed.27504556.s4.e0" text="Warfarin" /></sentence><sentence text=" Drug-drug interaction and regular monitoring with Warfarin pose a significant challenge where health care system has limited resources; and lack of a well-structured health system, hinders regular International Normalized Ratio (INR) monitoring" /><sentence text=" Novel oral anticoagulants (NOACs) have opened up a new exciting chapter in the field of anticoagulation in non-valvular atrial fibrillation (NVAF)" /><sentence text=" This review discussed the landmark trials that led to the development of NOACs and explored the potentials of these new agents with simultaneous comparison of Warfarin"><entity charOffset="160-168" id="DDI-PubMed.27504556.s7.e0" text="Warfarin" /></sentence><sentence text=" " /></document>